Recombinant Human APOA2, N-SUMO

Description of Recombinant Human APOA2, N-SUMO

Introduction

Recombinant Human APOA2, N-SUMO is a genetically engineered protein that has been modified with a small ubiquitin-like modifier (SUMO) tag at its N-terminus. This modification allows for improved stability and solubility of the protein, making it an ideal candidate for use in drug targeting and protein research.

Structure of Recombinant Human APOA2, N-SUMO

The structure of Recombinant Human APOA2, N-SUMO is composed of two main components: the APOA2 protein and the SUMO tag. APOA2 is a 77 amino acid long protein that is primarily found in high-density lipoproteins (HDL) and plays a crucial role in lipid metabolism. The SUMO tag is a small protein that is attached to the N-terminus of APOA2 through a covalent bond. This tag consists of 97 amino acids and is responsible for the improved stability and solubility of the recombinant protein.

Activity of this protein

The primary activity of Recombinant Human APOA2, N-SUMO is its ability to bind to lipids and transport them through the blood. APOA2 has a high affinity for cholesterol and other fatty acids, allowing it to form complexes with these molecules and transport them to various tissues in the body. The addition of the SUMO tag does not alter the binding activity of APOA2, but it does improve the overall stability of the protein. This allows for a longer half-life and increased effectiveness in lipid transport.

In addition to its lipid transport activity, Recombinant Human APOA2, N-SUMO also has anti-inflammatory properties. APOA2 has been shown to inhibit the production of inflammatory cytokines and chemokines, making it a potential therapeutic target for inflammatory diseases.

Application as a Drug Target

The unique structure and activity of Recombinant Human APOA2, N-SUMO make it an attractive drug target for various diseases. Its ability to bind to lipids and transport them through the blood makes it a potential target for treating disorders related to lipid metabolism, such as dyslipidemia and atherosclerosis. The anti-inflammatory properties of APOA2 also make it a promising target for inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

One potential application of Recombinant Human APOA2, N-SUMO as a drug target is in the development of novel therapies for dyslipidemia. By targeting APOA2, researchers can potentially increase the levels of HDL in the blood, which has been shown to have a protective effect against cardiovascular diseases. This could lead to the development of new drugs that can effectively lower cholesterol levels and reduce the risk of heart disease.

Another potential application is in the treatment of inflammatory diseases. By targeting APOA2, researchers can potentially reduce the production of inflammatory cytokines and chemokines, which are responsible for the symptoms of these diseases. This could lead to the development of new therapies that can effectively manage inflammation and improve the quality of life for patients.

Conclusion

Recombinant Human APOA2, N-SUMO is a genetically engineered protein that has been modified with a SUMO tag for improved stability and solubility. Its structure is composed of APOA2 and the SUMO tag, and its primary activity is the transport of lipids and anti-inflammatory effects. This unique protein has potential applications as a drug target for dyslipidemia and inflammatory diseases. Further research and development of Recombinant Human APOA2, N-SUMO could lead to the development of novel therapies for these diseases, improving the lives of many individuals.